GlaxoSmithKline is in China.

GlaxoSmithKline's history in China can be traced back to the early 20th century. Since 1980s, inspired by the reform and opening-up policy of China government, the company has actively invested in China, and introduced the most advanced pharmaceutical technology, the best quality products, the latest business model, the most modern management concepts and marketing skills to China.

With the global merger of GlaxoSmithKline Wellcome Company and SmithKline Bicheng Company from June 5 to 438, 2000, GlaxoSmithKline Company became one of the largest pharmaceutical companies in the world. At the beginning of 200 1, GlaxoSmithKline (China) Investment Co., Ltd. was established and became one of the largest multinational pharmaceutical enterprises in China. The company's business consists of prescription drugs, over-the-counter drugs, vaccines and consumer health products. The main business parts are located in Shanghai, Tianjin, Beijing and Hong Kong. Headquartered in Beijing.

GlaxoSmithKline's performance in China continues to grow. The total sales in 2002 increased by 17% compared with that in 2006, and the shares of prescription department, Sino-US SmithKline, vaccine department and consumer health products were 5 1%, 29%, 7% and 13% respectively.

GlaxoSmithKline was one of the first foreign pharmaceutical companies to successfully establish a joint venture in China, among which GlaxoSmithKline in the United States and GlaxoSmithKline in Chongqing were both famous "double-excellent" enterprises in China. Since entering China for nearly 20 years, the company has established seven registered companies, five of which are joint ventures with a registered capital of US$ 230 million. The company has set up offices in 32 major cities in China, including Hongkong. At present, it has more than 2,500 employees in China, and has trained a large number of high-quality business managers and technical backbones.